title: High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains.
abstract: The compound UIC-94017 (TMC-114) is a second-generation HIV protease inhibitor with improved pharmacokinetics that is chemically related to the clinical inhibitor amprenavir. UIC-94017 is a broad-spectrum potent inhibitor active against HIV-1 clinical isolates with minimal cytotoxicity. We have determined the high-resolution crystal structures of UIC-94017 in complexes with wild-type HIV-1 protease (PR) and mutant proteases PR(V82A) and PR(I84V) that are common in drug-resistant HIV. The structures were refined at resolutions of 1.10-1.53A. The crystal structures of PR and PR(I84V) with UIC-94017 ternary complexes show that the inhibitor binds to the protease in two overlapping positions, while the PR(V82A) complex had one ordered inhibitor. In all three structures, UIC-94017 forms hydrogen bonds with the conserved main-chain atoms of Asp29 and Asp30 of the protease. These interactions are proposed to be critical for the potency of this compound against HIV isolates that are resistant to multiple protease inhibitors. Other small differences were observed in the interactions of the mutants with UIC-94017 as compared to PR. PR(V82A) showed differences in the position of the main-chain atoms of residue 82 compared to PR structure that better accommodated the inhibitor. Finally, the 1.10A resolution structure of PR(V82A) with UIC-94017 showed an unusual distribution of electron density for the catalytic aspartate residues, which is discussed in relation to the reaction mechanism.
authors.affiliation: Department of Chemistry, Georgia State University, Atlanta, GA 30303, USA.
authors.forename: Yunfeng
authors.initials: Y
authors.lastname: Tie
authors.forename: Peter I
authors.initials: PI
authors.lastname: Boross
authors.forename: Yuan-Fang
authors.initials: YF
authors.lastname: Wang
authors.forename: Laquasha
authors.initials: L
authors.lastname: Gaddis
authors.forename: Azhar K
authors.initials: AK
authors.lastname: Hussain
authors.forename: Sofiya
authors.initials: S
authors.lastname: Leshchenko
authors.forename: Arun K
authors.initials: AK
authors.lastname: Ghosh
authors.forename: John M
authors.initials: JM
authors.lastname: Louis
authors.forename: Robert W
authors.initials: RW
authors.lastname: Harrison
authors.forename: Irene T
authors.initials: IT
authors.lastname: Weber
mesh_terms: D001224:Aspartic Acid / Q000737:chemistry; D020134:Catalytic Domain; D018360:Crystallography, X-Ray; D000069454:Darunavir; D024921:Drug Resistance, Multiple, Viral; D016333:HIV Protease / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism; D017320:HIV Protease Inhibitors / Q000737:chemistry* / Q000378:metabolism; D015497:HIV-1 / Q000201:enzymology; D006801:Humans; D008958:Models, Molecular; D015394:Molecular Structure; D013449:Sulfonamides / Q000737:chemistry* / Q000378:metabolism
chemical_list: D017320:HIV Protease Inhibitors; D013449:Sulfonamides; D001224:Aspartic Acid; D016333:HIV Protease; D000069454:Darunavir